Efgartigimod developed by Argenx is a strong competitor to Soliris.
Syntimmune
Posted inAutoimmune Diseases, Mergers & Acquisitions, Rare/Orphan Diseases
AstraZeneca + Alexion = Rescue of Both Companies
Alexion Pharmaceuticals, which owns Soliris, one of the most expensive drugs on Earth, has agreed to sell AstraZeneca for $39 billion.